December 19, 2022
Another great event by Recipharm organized by Helen Domeshek,PhD! Thank you for this fun and informative evening 🍻 Great opportunity to discuss with colleagues and friends about #fundraising #ipo #croudfunding #bussinessdevelopment and more! Great job by our CEO Dr. Lior Shaltiel, PhD telling NurExone Biologic‘s story Read More …
NurExone Biologic Ltd., an Israeli biopharmaceutical company aiming to revolutionize the treatment of spinal cord injury (SCI), is leveraging its proprietary technologies into a platform technology company with a potentially diverse portfolio of novel, cutting-edge therapies for several CNS traumatic indications. Read More …
We started our journey to provide much-needed therapy for people who have suffered spinal cord injuries and have accomplished very significant achievements in 2022. As we progress with developing our underlying technology, the awareness of a greater picture has intensified. The same technologies and science that will serve NurExone may
The Company agreed to settle debts in the aggregate amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at the market price on November 24, 2022 of CAD$0.38 per share. These debts were incurred prior to the recent Reverse Takeover Transaction following which NurExone began trading
Join us at Dublin Pub, Rehovot on Wednesday, 14th of December, to hear our CEO Dr. Lior Shaltiel, PhD share insights about #IPO, #funding at the #healthtech industry and more…! Read More…
In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients. With at least 22,143 scientific articles published about exosomes and 253 clinical trials underway, these small vesicles have intriguing potential to be used within a
Good job for Dr. Lior Shaltiel, PhD and Inbar Paz Benayoun, Adv. for the successful and effective business trip to London last week! Representing the company in an OTC Markets Group event and exploring new opportunities and collaborations! Read More …
Thanks to Nurexone’s performance in recent weeks on the TSXV compared to the market, it has received the badge – shows up on NurExone’s page on the TMX website – and it is now listed on the top healthcare page. Read More …
NurExone Biologic‘s team members Dr. Lior Shaltiel, PhD and Inbar Paz Benayoun, Adv. will attend The OTC Markets Group OTCQX Annual Issuer’s Forum in London. Another great opportunity to expand business strategies, synergies and developments with partners and colleagues! Read More …